SPPL2B

Across TCGA pan-cancer cohorts, SPPL2B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SPPL2B data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher SPPL2B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SPPL2B expression acts as an unfavorable survival marker.

BRCA, KIRC, and UCEC are the cancer types where SPPL2B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.112	0.578	.006	24	view →
KIRC	OS	Median	All	0.141	0.655	.026	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SPPL2B–BRCA (OS)

Open the BRCA breakdown →